Sharmilan Thanendrarajan MD

PubMed

• Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma.
  Samer Al Hadidi, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey
  Blood Advances. 2025-02-25
• Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma.
  Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy Jr, Fenghuang Zhan
  Blood Advances. 2025-02-12
• 1 citations
  Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.
  Yan Cheng, Fumou Sun, Daisy V Alapat, Visanu Wanchai, David Mery
  Blood Cancer Journal. 2024-11-06

Journal Articles

• Mesenchymal Stem Cells Gene Signature in High‐Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2‐Expressing Small Adipocytes  
  Bart Barlogie, Sharmilan Thanendrarajan, Carolina Schinke, British Journal of Haematology

Abstracts/Posters

• The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Mutational Landscape of Primary Plasma Cell Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all